Pulmonary function testing (PFT) is an indispensable tool in the diagnosis, monitoring, and management of respiratory diseases. However, interpretation of PFT results can be complex due to the multitude of factors influencing lung function. This article aims to provide a comprehensive guide to aid healthcare professionals in interpreting these results effectively.
Spirometry is the most common PFT, measuring the volume and speed of air a patient can inhale and exhale. The key parameters are Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and their ratio (FEV1/FVC). A reduced FEV1/FVC ratio indicates obstructive lung disease, while a reduced FVC with a normal FEV1/FVC ratio suggests restrictive lung disease.
Diffusing capacity of the lungs for carbon monoxide (DLCO) measures the ability of the lungs to transfer gas from inhaled air to the red blood cells. A decreased DLCO may indicate emphysema, pulmonary fibrosis, or pulmonary vascular disease.
Residual volume (RV), total lung capacity (TLC), and functional residual capacity (FRC) are important in diagnosing lung diseases. Increased RV and FRC suggest air trapping seen in obstructive diseases, while decreased TLC indicates restrictive diseases.
Assessing bronchodilator responsiveness helps differentiate between asthma and Chronic Obstructive Pulmonary Disease (COPD). An increase in FEV1 or FVC by 12% and 200ml after bronchodilator use is suggestive of asthma.
Interpreting PFTs is a complex task requiring understanding of various parameters and their implications. However, with a systematic approach, healthcare professionals can accurately diagnose and manage respiratory diseases. Continuous learning and experience are key to mastering this vital skill.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation